Search

Your search keyword '"de Freitas, Caroline S."' showing total 30 results

Search Constraints

Start Over You searched for: Author "de Freitas, Caroline S." Remove constraint Author: "de Freitas, Caroline S."
30 results on '"de Freitas, Caroline S."'

Search Results

1. Extracellular vesicles from primary human macrophages stimulated with VIP or PACAP mediate anti-SARS-CoV-2 activities in monocytes through NF-κB signaling pathway

3. SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes

4. Correction: SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes

6. Severe influenza infection is associated with inflammatory programmed cell death in infected macrophages

7. Macrophages undergo necroptosis during severe influenza A infection and contribute to virus-associated cytokine storm

8. VIP plasma levels associate with survival in severe COVID-19 patients, correlating with protective effects in SARS-CoV-2-infected cells

9. Simvastatin Downregulates the SARS-CoV-2-Induced Inflammatory Response and Impairs Viral Infection Through Disruption of Lipid Rafts

10. In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19

11. Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators

12. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production

13. SARS-CoV-2 induces inflammasome-dependent pyroptosis and downmodulation of HLA-DR in human monocytes, which can be prevented by atazanavir

14. Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators

15. VIP plasma levels associate with survival in severe COVID-19 patients, correlating with protective effects in SARS-CoV-2-infected cells

16. The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2

17. Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production

18. Neuraminidase from Influenza A and B Viruses is Susceptible to the Compound 4-(4-Phenyl-1H-1,2,3-Triazol-1-yl)-2,2,6,6-Tetramethylpiperidine-1- Oxyl

19. Agathisflavone, a Biflavonoid from Anacardium occidentale L., Inhibits Influenza Virus Neuraminidase

21. Corrigendum: The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication

22. Beyond Members of the Flaviviridae Family, Sofosbuvir Also Inhibits Chikungunya Virus Replication

23. Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo

24. Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication

25. Correction: Corrigendum: The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication

26. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication

27. The clinically approved antiviral drug sofosbuvir impairs brazilian zika virus replication

28. Correction: Aureonitol, a Fungi-Derived Tetrahydrofuran, Inhibits Influenza Replication by Targeting Its Surface Glycoprotein Hemagglutinin

29. Aureonitol, a Fungi-Derived Tetrahydrofuran, Inhibits Influenza Replication by Targeting Its Surface Glycoprotein Hemagglutinin

30. Beyond Members of the FlaviviridaeFamily, Sofosbuvir Also Inhibits Chikungunya Virus Replication

Catalog

Books, media, physical & digital resources